| Therapy with zoledronic acid, 5 mg, for a patient with Paget disease of bone. | |
| | |
MedLine Citation:
|
PMID: 18753106 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To describe the effects of an infusion of zoledronic acid in a patient with Paget disease of bone (PD) who had been treated unsuccessfully with several other bisphosphonates. METHODS: The patient's treatment history is described, and his response to various bisphosphonates, including zoledronic acid, is discussed. RESULTS: The patient was a 61-year-old man when a diagnosis of PD was made on the basis of an elevated serum alkaline phosphatase (ALP) level of 391 U/L (reference range, 45 to 135). Pagetic bone changes were noted on bone scan and x-ray examinations. Treatment with etidronate had no effect on ALP levels. This intervention was followed by 2 courses of intravenous therapy with pamidronate, which decreased ALP levels by 57% and 55% without inducing a remission. Subsequent oral treatment with alendronate and then risedronate yielded unsustained biochemical remissions of 6 months each. Most recently, therapy with an infusion of 5 mg of zoledronic acid induced a remission that is thus far 20 months in duration. With this therapy, the patient has experienced no side effects, and he has noted a decrease in bone pain. CONCLUSION: This case study shows that a patient with PD who received successive treatments with several bisphosphonates with inadequate responses or only brief remissions was more effectively treated with a single 5-mg infusion of zoledronic acid. This patient's therapeutic responses illustrate the relative efficacy of available bisphosphonates and the potential for longer-lasting remissions with zoledronic acid in patients with PD. |
| | |
Authors:
|
Joseph R Tucci |
Related Documents
:
|
20804676 - Physeal change after tuberculous osteomyelitis of the long bone in children. 15926166 - No difference between prednisolone and dexamethasone treatment in bone mineral density ... 8050236 - Percutaneous intramedullary fixation of long bone deformity in severe osteogenesis impe... 15685456 - The effect of low-intensity pulsed ultrasound on callus maturation in tibial distractio... 15093636 - Safety and efficacy of a dexamethasone anterior segment drug delivery system in patient... 23413226 - Hybrid perventricular device closure of doubly committed subarterial ventricular septal... |
Publication Detail:
|
Type: Case Reports; Journal Article |
Journal Detail:
|
Title: Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists Volume: 14 ISSN: 1934-2403 ISO Abbreviation: Endocr Pract Publication Date: 2008 Jul-Aug |
Date Detail:
|
Created Date: 2008-08-28 Completed Date: 2009-01-14 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9607439 Medline TA: Endocr Pract Country: United States |
Other Details:
|
Languages: eng Pagination: 607-10 Citation Subset: IM |
Affiliation:
|
Division of Endocrinology, Roger Williams Medical Center, Providence, RI 02908-4728, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Bone Density Conservation Agents
/
administration & dosage,
therapeutic use Diphosphonates / administration & dosage, therapeutic use* Humans Imidazoles / administration & dosage, therapeutic use* Male Middle Aged Osteitis Deformans / drug therapy*, pathology Remission Induction Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Bone Density Conservation Agents; 0/Diphosphonates; 0/Imidazoles; 118072-93-8/zoledronic acid |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Familial paragangliomas: case report and literature review.
Next Document: Plasma cell granuloma of the thyroid: report of case and review of literature.